Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc.（BCLI）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BCLI · 截至 2026年6月8日
活动摘要
买入笔数
13
P-Purchase only
卖出笔数
1
近12个月
买卖比
13.00
Buy/Sell (by trades)
整体情绪
Brainstorm Cell Therapeutics Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BCLI 季度内部人买卖趋势
BCLI 内幕交易卖出 · BCLI 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BCLI CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BCLI 高管卖出股份 · BCLI 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 26, 2026 | Lebovits Chaim President & CEO | Award | 1,800,000 | — | Form 4 |
| Feb 26, 2026 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 150,000 | — | Form 4 |
| Feb 26, 2026 | Patlis Alla See Remarks | Award | 100,000 | — | Form 4 |
| Feb 26, 2026 | FRENKEL JACOB A Director | Award | 200,000 | — | Form 4 |
| Feb 26, 2026 | ARBEL IRIT Director | Award | 120,000 | — | Form 4 |
| Jan 1, 2025 | Dagher Ibrahim B. Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Jan 1, 2025 | Lebovits Chaim President & CEO | Award | 120,000 | — | Form 4 |
| Jan 1, 2025 | FRENKEL JACOB A Director | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Polverino Anthony J. Director | Award | 24,000 | — | Form 4 |
| Jan 1, 2025 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 20,000 | — | Form 4 |
| Jan 1, 2025 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Patlis Alla See Remarks | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Naor Nir Director | Award | 30,666 | — | Form 4 |
| Jan 1, 2025 | Lindborg Stacy Director | Award | 20,000 | — | Form 4 |
| Jan 1, 2025 | HARTOUNIAN HARTOUN EVP, Chief Operating Officer | Award | 50,000 | — | Form 4 |
| Jan 1, 2025 | Bairu Menghisteab Director | Award | 24,000 | — | Form 4 |
| Jan 1, 2025 | ARBEL IRIT Director | Award | 30,666 | — | Form 4 |
| Sep 30, 2024 | Lebovits Chaim President & CEO | Purchase | 22,000 | $5K | Form 4 |
| Oct 1, 2024 | Lebovits Chaim President & CEO | Purchase | 1,836 | $6K | Form 4 |
| Jul 19, 2024 | Dagher Ibrahim B. Chief Medical Officer | Sale | 63,000 | $22K | Form 4 |
| Jun 24, 2024 | HARTOUNIAN HARTOUN EVP, Chief Operating Officer | Award | 30,000 | — | Form 4 |
| May 28, 2024 | Lebovits Chaim President & CEO | Award | 15,000 | $8K | Form 4 |
| May 22, 2024 | Lebovits Chaim President & CEO | Award | 25,000 | $16K | Form 4 |
| May 21, 2024 | Lebovits Chaim President & CEO | Award | 25,000 | $14K | Form 4 |
| May 13, 2024 | Lebovits Chaim President & CEO | Award | 10,000 | $5K | Form 4 |
Yablonka Uri
EVP & Chief Business Officer · Director
日期
Feb 26
股数
150,000
均价
—
总金额
—
Yablonka Uri
EVP & Chief Business Officer · Director
日期
Jan 1
股数
20,000
均价
—
总金额
—
Yablonka Uri
EVP & Chief Business Officer · Director
日期
Jan 1
股数
40,000
均价
—
总金额
—
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BCLI 内幕交易
BCLI 内幕交易
Brainstorm Cell Therapeutics Inc.（BCLI）内幕交易数据来源于公司内部人（包括Lebovits Chaim (President & CEO), Yablonka Uri (EVP & Chief Business Officer · Director), Patlis Alla (See Remarks)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BCLI内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Brainstorm Cell Therapeutics Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BCLI 内幕交易 · 5个问题Brainstorm Cell Therapeutics Inc.（BCLI）的内部人包括高管和董事，如Lebovits Chaim (President & CEO), Yablonka Uri (EVP & Chief Business Officer · Director), Patlis Alla (See Remarks)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026